A JAK2-V617F activating mutation in addition to KIT and FLT3 mutations is associated with clinical outcome in patients with t(8;21)(q22;q22) acute myeloid leukemia.
作者信息
Iwanaga Eisaku, Nanri Tomoko, Matsuno Naofumi, Kawakita Toshiro, Mitsuya Hiroaki, Asou Norio
出版信息
Haematologica. 2009 Mar;94(3):433-5. doi: 10.3324/haematol.13283. Epub 2009 Jan 30.
Abstract
摘要
相似文献
1
A JAK2-V617F activating mutation in addition to KIT and FLT3 mutations is associated with clinical outcome in patients with t(8;21)(q22;q22) acute myeloid leukemia.除KIT和FLT3突变外，JAK2-V617F激活突变与t(8;21)(q22;q22)急性髓系白血病患者的临床结局相关。
Haematologica. 2009 Mar;94(3):433-5. doi: 10.3324/haematol.13283. Epub 2009 Jan 30.
2
Importance of c-kit mutation detection method sensitivity in prognostic analyses of t(8;21)(q22;q22) acute myeloid leukemia.c-kit 基因突变检测方法灵敏度在 t(8;21)(q22;q22) 急性髓系白血病预后分析中的重要性。
Leukemia. 2011 Sep;25(9):1423-32. doi: 10.1038/leu.2011.104. Epub 2011 May 24.
3
Extramedullary tumors presenting double vision in patients with t(8;21)(q22;q22) acute myeloid leukemia lacking mutations in the receptor tyrosine kinase genes KIT or FLT3.在缺乏受体酪氨酸激酶基因KIT或FLT3突变的t(8;21)(q22;q22)急性髓系白血病患者中出现复视的髓外肿瘤
Leuk Res. 2010 Dec;34(12):e320-2. doi: 10.1016/j.leukres.2010.07.028. Epub 2010 Aug 10.
4
[Analysis of c-kit and JAK2 gene mutations in t(8;21) acute myeloid leukemia].t(8;21)急性髓系白血病中c-kit和JAK2基因突变分析
Zhonghua Xue Ye Xue Za Zhi. 2008 Dec;29(12):797-801.
5
Cytogenetic analysis of acute myeloid leukemia with t(8;21) from a tertiary care center in India with correlation between clinicopathologic characteristics and molecular analysis.印度一家三级护理中心伴 t(8;21)的急性髓系白血病的细胞遗传学分析及其与临床病理特征和分子分析的相关性。
Leuk Lymphoma. 2012 Jan;53(1):103-9. doi: 10.3109/10428194.2011.603447. Epub 2011 Sep 2.
6
Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome.监测核心结合因子急性髓系白血病患者的微小残留病，以及 C-KIT、FLT3 和 JAK2 突变对临床结局的影响。
Leuk Lymphoma. 2009 Sep;50(9):1448-60. doi: 10.1080/10428190903085951.
7
AML with t(8;21) and trisomy 4: possible involvement of c-kit?伴有t(8;21)和4号染色体三体的急性髓系白血病：c-kit可能受累？
Leukemia. 2003 Sep;17(9):1915; author reply 1915-6. doi: 10.1038/sj.leu.2403066.
8
Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG).伴有 inv(16) 或 t(16;16) 的急性髓系白血病中的二次遗传病变：德国-奥地利急性髓系白血病研究组（AMLSG）的研究。
Blood. 2013 Jan 3;121(1):170-7. doi: 10.1182/blood-2012-05-431486. Epub 2012 Oct 31.
9
Acute myeloid leukemia with t(8;21)(q22;q22.1)/RUNX1-RUNX1T1 and KIT Exon 8 mutation is associated with characteristic mastocytosis and dismal outcomes.伴 t(8;21)(q22;q22.1)/RUNX1-RUNX1T1 和 KIT 外显子 8 突变的急性髓系白血病与特征性肥大细胞增多症和不良预后相关。
Exp Mol Pathol. 2019 Jun;108:131-136. doi: 10.1016/j.yexmp.2019.04.009. Epub 2019 Apr 17.
10
[Tyrosine kinase mutation and acute myeloid leukemia with T (8; 21)].[酪氨酸激酶突变与伴t(8;21)的急性髓系白血病]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Aug;17(4):866-9.
引用本文的文献
1
Transformation into acute myeloid leukemia with t(8;21)(q22;q22.1); RUNX1::RUNX1T1 from JAK2-mutated essential thrombocythemia: a case report.从 JAK2 突变型原发性血小板增多症转化为急性髓系白血病伴 t(8;21)(q22;q22.1);RUNX1::RUNX1T1：一例报告。
J Med Case Rep. 2024 Aug 18;18(1):372. doi: 10.1186/s13256-024-04691-0.
2
Prognostic Significance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis.核心结合因子急性髓系白血病中KIT突变的预后意义：一项系统评价和荟萃分析
PLoS One. 2016 Jan 15;11(1):e0146614. doi: 10.1371/journal.pone.0146614. eCollection 2016.
3
Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic.急性髓系白血病中的小分子抑制剂：从实验室到临床
Expert Rev Hematol. 2014 Aug;7(4):439-64. doi: 10.1586/17474086.2014.932687.
4
JAK inhibitors suppress t(8;21) fusion protein-induced leukemia.JAK 抑制剂抑制 t(8;21)融合蛋白诱导的白血病。
Leukemia. 2013 Dec;27(12):2272-9. doi: 10.1038/leu.2013.197. Epub 2013 Jul 1.
5
Gene mutations and molecularly targeted therapies in acute myeloid leukemia.急性髓系白血病中的基因突变与分子靶向治疗
Am J Blood Res. 2013;3(1):29-51. Epub 2013 Jan 17.
6
Relevance of JAK2V617F positivity to hematological diseases--survey of samples from a clinical genetics laboratory.JAK2V617F 阳性与血液疾病的相关性——临床遗传学实验室样本调查。
J Hematol Oncol. 2011 Jan 14;4:4. doi: 10.1186/1756-8722-4-4.
7
8
Successful treatment with low-dose imatinib mesylate of therapy-related myeloid neoplasm harboring TEL-PDGFRB in a patient with acute promyelocytic leukemia.急性早幼粒细胞白血病患者中携带TEL-PDGFRB的治疗相关髓系肿瘤经低剂量甲磺酸伊马替尼成功治疗。
Haematologica. 2010 Sep;95(9):e1. doi: 10.3324/haematol.2010.27656.
本文引用的文献
1
JAK2-V617F activating mutation in acute myeloid leukemia: prognostic impact and association with other molecular markers.急性髓系白血病中的JAK2-V617F激活突变：预后影响及与其他分子标志物的关联
Leukemia. 2007 Nov;21(11):2386-90. doi: 10.1038/sj.leu.2404812. Epub 2007 Jun 21.
2
Tyrosine kinase mutations of JAK2 are rare events in AML but influence prognosis of patients with CBF-leukemias.JAK2的酪氨酸激酶突变在急性髓系白血病中是罕见事件，但会影响核心结合因子白血病患者的预后。
Haematologica. 2007 Jan;92(1):137-8. doi: 10.3324/haematol.10489.
3
Jak2: normal function and role in hematopoietic disorders.Jak2：正常功能及其在造血系统疾病中的作用
Curr Opin Genet Dev. 2007 Feb;17(1):8-14. doi: 10.1016/j.gde.2006.12.009. Epub 2007 Jan 8.
4
JAK2 seems to be a typical cooperating mutation in therapy-related t(8;21)/ AML1-ETO-positive AML.
Leukemia. 2007 Jan;21(1):183-4. doi: 10.1038/sj.leu.2404465. Epub 2006 Nov 9.
5
JAK2V617F mutations as cooperative genetic lesions in t(8;21)-positive acute myeloid leukemia.
Haematologica. 2006 Nov;91(11):1569-70. Epub 2006 Oct 17.
6
Identification of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukaemia with t(8;21)/AML1-ETO.伴有t(8;21)/AML1-ETO的急性髓系白血病中其他细胞遗传学和分子遗传学异常的鉴定
Br J Haematol. 2006 Sep;134(6):616-9. doi: 10.1111/j.1365-2141.2006.06229.x.
7
JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status.原发性血小板增多症患者血小板中的JAK2V617F突变：与临床特征的相关性及STAT5磷酸化状态分析
Eur J Haematol. 2006 Sep;77(3):210-6. doi: 10.1111/j.1600-0609.2006.00688.x.
8
Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study.c-KIT突变在核心结合因子白血病中的预后影响：一项意大利回顾性研究。
Blood. 2006 May 1;107(9):3463-8. doi: 10.1182/blood-2005-09-3640. Epub 2005 Dec 29.
9
A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.一项针对成人急性髓系白血病患者的随机缓解后比较研究：标准剂量巩固治疗四个疗程且不进行维持治疗与标准剂量巩固治疗三个疗程并进行维持治疗的对比——日本成人白血病研究组AML 97研究
Cancer. 2005 Dec 15;104(12):2726-34. doi: 10.1002/cncr.21493.
10
The JAK2 V617F mutation in de novo acute myelogenous leukemias.初发急性髓系白血病中的JAK2 V617F突变
Oncogene. 2006 Mar 2;25(9):1434-6. doi: 10.1038/sj.onc.1209163.
Zotero 插件